BioRexis™ Pharmaceutical Corporation uses its unique fusion technology platform to enhance the half-life, efficacy and safety of therapeutic proteins and peptides.
BioRexis’ proprietary approach to protein engineering uses a natural variant of the human plasma protein transferrin as a scaffold for the effective presentation of proteins and peptides. The same patented technology is also used to create Trans-bodies™, which can replace conventional monoclonal antibodies (“MAbs”). Both are produced in cost-effective and highly efficient yeast expression systems.
Transferrin has a half-life of 7-14 days. BioRexis’ fusion technology can thus allow a peptide that has a half-life of minutes to be dosed once weekly or less.